Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies
Ana Giménez-Arnau,
Martin Metz,
Michihiro Hide,
Vipul Jain,
Abdallah Khemis,
Mark Lebwohl,
Michael J. Palumbo,
Sarbjit Saini,
Ekin Şavk,
Gordon Sussman,
Robert Szalewski,
Irena Walecka Herniczek,
Hugh Windom,
Bin Yang,
Sibylle Haemmerle,
Karine Lheritier,
Paula G.P. Machado,
El-Djouher Martzloff,
Noriko Seko,
Pengpeng Wang,
Artem Zharkov,
Marcus Maurer
